RPID Stock Forecast: Rapid Micro Biosystems, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Rapid Micro Biosystems, Inc. hold a median 12-month price target of $0.75 — +2.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 36 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Rapid Micro Biosystems, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (18): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
RPID stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RPID, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | Roth Capital | Initiates | Buy | $3.00 |
| 29 May 2026 | Keybanc | Maintains | Overweight | $8.00 → $5.00 |
| 22 May 2026 | Lake Street | Maintains | Buy | $8.00 → $7.00 |
| 28 July 2025 | Lake Street | Initiates | Buy | — |
| 12 Feb 2025 | Keybanc | Initiates | Overweight | — |
| 7 Mar 2023 | Morgan Stanley | Reiterates | Equal-Weight | — |
| 16 Aug 2022 | JP Morgan | Downgrade | Neutral | — |
| 11 May 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 Mar 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 15 Feb 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 15 Nov 2021 | Morgan Stanley | Maintains | Equal-Weight | — |
| 9 Aug 2021 | Cowen & Co. | Initiates | Outperform | — |
| 9 Aug 2021 | JP Morgan | Initiates | Overweight | — |
| 9 Aug 2021 | Morgan Stanley | Initiates | Equal-Weight | — |
| 9 Aug 2021 | Stifel | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RPID.
This page is one stock. Monday covers all of them.
RPID appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
RPID vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Rapid Micro Biosystems, Inc. returned −81.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
RPID analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.0×
- Price / book
- 4.1×
- EV / EBITDA
- —
Cheaper than 65% of US stocks
Cheaper than 23% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 15.0%
- Operating margin
- —
- Net margin
- —
Higher than 14% of US stocks
- Return on equity
- −191.8%
- Return on assets
- −45.7%
- Dividend yield
- —
Higher than 8% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Rapid Micro Biosystems, Inc. has a market value of $37.4M and an enterprise value of $52.4M.
Revenue in the twelve months to 30 June 2026: $35.2M. The latest quarter grew 10.9% year on year.
Net income over the same four quarters: −$51.2M, a −145.6% net margin.
Diluted earnings per share, trailing twelve months: −$1.12.
Free cash flow in the twelve months to 30 June 2026: −$40.4M.
Rapid Micro Biosystems, Inc. employs 171 people — $206K of revenue per employee.
Data provided by Twelve Data
RPID and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at RPID’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Rapid Micro Biosystems, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about RPID
What is the RPID stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Rapid Micro Biosystems, Inc. have a median 12-month price target of $0.75, with estimates ranging from $0.75 to $8. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is RPID stock a buy right now?
Of the 4 analysts covering Rapid Micro Biosystems, Inc., 2 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rapid Micro Biosystems, Inc. 36 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RPID?
As at 21 Nov 2026, Rapid Micro Biosystems, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).
Will RPID stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +2.0% from the last close, and Ticker Nerd's factor model ranks Rapid Micro Biosystems, Inc. 36 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the RPID stock forecast for 2030?
No analyst covering Rapid Micro Biosystems, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RPID are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.75 to $8 over the next 12 months.
How has RPID stock performed over the past year?
Rapid Micro Biosystems, Inc. returned -81.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Rapid Micro Biosystems, Inc. do?
Rapid Micro Biosystems Inc. Class A Common Stock represents ownership in Rapid Micro Biosystems, a life sciences technology company focused on automated microbial quality control for the pharmaceutical and biopharmaceutical industries. The company develops mission-critical solutions that help manufacturers detect microbial contamination and support the efficient manufacturing and safe release of healthcare products.
About Rapid Micro Biosystems, Inc.
Rapid Micro Biosystems Inc. Class A Common Stock represents ownership in Rapid Micro Biosystems, a life sciences technology company focused on automated microbial quality control for the pharmaceutical and biopharmaceutical industries. The company develops mission-critical solutions that help manufacturers detect microbial contamination and support the efficient manufacturing and safe release of healthcare products. Its current offerings include the Growth Direct platform, which combines an automated system, proprietary consumables, software for laboratory information management system connectivity, and validation and support services. These products are used across regulated environments involved in biologics, vaccines, cell and gene therapies, sterile injectables, medical devices, and personal care products. Headquartered in Lexington, Massachusetts, Rapid Micro Biosystems serves customers in the United States and international markets, where faster and more reliable microbial testing plays an important role in modern production workflows.
CEO Mr. Robert G. Spignesi Jr. · 171 employees · United States · https://www.rapidmicrobio.com